Hepatitis B Community
wonderfull presentation of easl 2011 conference results
About This Community:

This forum is an un-mediated, patient-to-patient forum for questions and support regarding Hepatitis B. Topics in this forum include but are not limited to, Causes, Diagnosis, Family and Relationships, Living With Hepatitis B, Research Updates, Treatment, Success Stories, Support, Symptoms.

Font Size:
Blank Blank

wonderfull presentation of easl 2011 conference results

most interesting findings:

sustained immune response only on those with:
cccdna equal or less than 5 copies/cell this is probably about hbsag 500iu/ml or less

exclusion of cirrhosis by fibroscan (most useful everyday tool to monitor liver damage/fibrosis)
>8kpa significant lesions, therapy necessary

hbsag level to predic seroclearance of hbv
hbsag<200 iu/ml  prediction of hbv clearance by 1-5years see table on file
hbsag<100iu/ml   prediction of hbv clearance by 1-5years see table on file
of course the lower hbsag the most probablility of hbv eradication

risk of liver cancer, at hbvdna undetactable 1.5% at 18years, very close to 0% at about 8 years (they dont say but this is probably without cirrhosis)

tables of hbsag decline in interferon+ antivirals combo etv or tnf or adv (on report interferon+tnf+etv) and eradication of hbv, see tables in file

tables about rep 9 ac replicor (probably a bomb therapy if combined with etv or tnf)
LB80380 for lam resistance mutants
gs9620 from gilead - the results of this on animals look too generic to say, i'd wait to see human trials because it looks like there is a relapse after end of therapy they used compound for too short time to have a real meaning

Related Discussions
Post a Comment
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources